A Synthetic Lethal Drug Reaches Patients Seven Years After Its Target Was Found

In 2019, several groups reported that cancers with a particular DNA repair defect depend for survival on an enzyme that healthy cells can do without. Seven years later, the first drug built on that observation has been tested in people. Results from the phase 1 trial were published in Nature Medicine in late September 2026, with an accompanying commentary on October 13 describing it as a synthetic lethal drug for microsatellite instability cancers.

The findings are a genuine proof of concept and a reminder of how much distance remains between a validated target and a useful medicine. The drug was tolerable, and three quarters of evaluable patients had their disease held in check. Only about one in ten saw their tumours shrink.

What synthetic lethality means

Two genes are synthetically lethal when losing either one alone is survivable but losing both kills the cell. In cancer this is a gift, because tumour cells have often already lost one of the pair through the mutations that made them cancerous. A drug that blocks the surviving partner should kill the tumour while leaving normal cells, which still have both, largely intact.

The established example is PARP inhibition in cancers with faulty BRCA1 or BRCA2. Those tumours have lost one route of DNA repair; blocking a second route with a PARP inhibitor is lethal to them specifically. The approach produced several approved drugs and made synthetic lethality one of the more sought-after concepts in oncology drug discovery.

Why MSI tumours need WRN

Microsatellite instability arises when a cell's mismatch repair system fails. Mismatch repair proofreads newly copied DNA and corrects the errors that polymerases make, and it is especially important across microsatellites: short sequences repeated many times over, where the copying machinery readily slips. Without proofreading, these repeats expand and contract freely, which is what the term instability describes.

MSI is found in a proportion of colorectal, endometrial, gastric and other tumours, and is the defining feature of cancers arising in Lynch syndrome, an inherited mismatch repair deficiency.

The 2019 work showed that these tumours become dependent on WRN, the Werner syndrome helicase, an enzyme that unwinds DNA. The expanded repeats accumulating in MSI cells can form awkward secondary structures that stall DNA replication, and WRN appears to be what resolves them. Microsatellite-stable cells manage without it. Remove WRN from an MSI cell and it dies; remove it from a normal cell and little happens. That is synthetic lethality in textbook form, and it made WRN one of the most attractive new targets in oncology.

Attractive did not mean easy. Helicases have been difficult to drug, because the pockets available on them tend to be shallow and the ATP-binding sites they use resemble those of many other enzymes, which invites off-target effects. Several groups spent years on the chemistry, and the compounds that emerged are covalent inhibitors, which gain selectivity by reacting with a specific amino acid residue on the target rather than relying on fit alone.

The trial

RO7589831, also known as VVD-133214, is a first-in-class covalent inhibitor of WRN, meaning it forms a lasting chemical bond with its target rather than binding reversibly. Part 1 of the first-in-human study was a dose escalation in 88 patients with advanced solid tumours showing microsatellite instability, deficient mismatch repair, or both. Doses ran from 150 mg once daily up to 1,000 mg twice daily and 600 mg three times daily.

On safety, the drug behaved well for a first pass. Only one dose-limiting toxicity occurred, grade 2 nausea in the highest three-times-daily cohort, and the maximum tolerated dose was never reached. Side effects were mostly mild to moderate: nausea in 54.5% of patients, diarrhoea in 43.2%, fatigue in 39.8%, anaemia in 37.5% and vomiting in 30.7%. Anaemia was the main severe toxicity, reaching grade 3 or worse in 11.4%, which is unsurprising for a drug interfering with DNA replication in a rapidly dividing tissue. Only 3.4% of patients stopped treatment because of side effects, and there were no treatment-related deaths.

On activity, the results are more mixed. Among 66 evaluable patients with MSI tumours:

• Disease control rate: 74.2% (49 of 66).
• Objective response rate: 10.6%, seven confirmed partial responses. No complete responses were reported.
• Median duration of response: 10.2 months and continuing.
• Median progression-free survival: 6.7 months (95% CI, 4.1 to 8.5).
• Median overall survival: 17.6 months.

The investigators selected 150 mg and 600 mg twice daily as recommended phase 2 doses for further optimization, and concluded that the drug has a manageable safety profile and warrants further testing.

It is worth noting what a phase 1 dose escalation is designed to do. Its job is to find a dose that patients can tolerate and to characterise what the drug does to the body, not to demonstrate benefit. Efficacy measures are secondary, collected opportunistically in patients who have usually run out of standard options and whose tumours differ widely in type and prior treatment. Reading them as a verdict on the drug would be a mistake in either direction.

How to read the numbers

A disease control rate of 74% alongside a response rate of 11% describes a drug that mostly stops tumours growing rather than shrinking them. In a dose-escalation study of heavily pretreated patients, that is a reasonable signal, and the median duration of response of more than ten months suggests the responses that did occur were durable.

Context matters here. MSI tumours are already the group that responds best to immune checkpoint inhibitors, because their high mutation burden makes them visible to the immune system. Patients reaching a phase 1 trial of a novel agent have typically exhausted those options. A WRN inhibitor is therefore being positioned for a population with real unmet need, but it will eventually have to justify itself against, or alongside, immunotherapy.

Limitations

• This is a phase 1 dose escalation, single-arm and uncontrolled. Disease control rate in particular is a soft endpoint without a comparator, since some tumours would have been stable anyway.
• Target engagement was not shown directly. The authors state they could not demonstrate WRN inhibition in tumour tissue, relying instead on exploratory circulating tumour DNA and PET metabolic responses as indirect evidence of biological activity. For a first-in-class covalent drug, that is a notable gap.
• Doses are not settled. No maximum tolerated dose was identified, and two different doses went forward for optimization, which means the right exposure is still an open question.
• Anaemia will need watching as exposure increases or treatment lengthens.
• Numbers are small. Seven responses among 66 patients cannot support claims about which subgroups benefit.

What to watch

• Dose-optimization results from part 2, and whether response rates improve at better-chosen exposures.
• Direct evidence of WRN engagement in tumours, through paired biopsies or a validated pharmacodynamic marker.
• Competing WRN programmes, including other inhibitors that have published discovery data, which will show whether the modest responses reflect this molecule or the target.
• Combination strategies, particularly with checkpoint inhibitors or chemotherapy, where a growth-arresting agent may be more useful than alone.
• Whether the synthetic lethal effect holds in tumours whose mismatch repair loss is acquired rather than inherited.

This article is for information only and is not medical advice. Treatment decisions should be made with a qualified clinician.

Sources: Nature Medicine (phase 1 trial); Nature Medicine (News & Views); Nature (WRN synthetic lethality, 2019); ClinicalTrials.gov NCT06004245